Survey Results Positive for New HAE Drug
Source: Hartaj Singh  (11/2/23)
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report. More >

Safety Profile of New IL-2 Molecule Better Than Like Drugs'
Source: Andres Maldonado  (11/2/23)
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report. More >

Firm To Present Trial Results Update at SITC Meeting
Source: Dr. David Nierengarten  (11/2/23)
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report. More >

Add Back Positions in This Biotech
Source: Chris Temple  (11/1/23)
Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs. More >

Biotech to Advance New Type 1 Diabetes Drug Into Clinic
Source: Edward White  (10/23/23)
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report. More >

Approval Likely in U.S., EU for New Drug for Prader-Willi
Source: Dr. Leland Gershell  (10/12/23)
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report. More >

Drug Reform Streaming Co. Starts Trading on CSE
Source: Streetwise Reports  (10/12/23)
This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement." More >

Chen Still Likes This Precious Metal in Q4
Source: Streetwise Reports  (10/9/23)
If you've been following asset manager Chen Lin's quarterly picks on Streetwise Reports, you know he is bullish on one particular precious metal, and the fourth quarter of 2023 is no exception. More >

Trial of New Drug for Acute Leukemia Meets Primary Endpoint
Source: Edward White  (10/5/23)
The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report. More >

New CAR-T Therapy Shows Potency in Certain Patients
Source: Dr. Jonathan Aschoff  (10/4/23)
Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report. More >

Biopharma Co. Adds CTO to Team
Source: Francois Brisebois  (9/21/23)
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report. More >

Trial Results Validate New Drug-Delivering Nasal Implant
Source: Matthew Caufield  (9/20/23)
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report. More >

Co. Reaches Major Milestone With Novel Drug
Source: Dr. Joseph Pantginis  (9/7/23)
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report. More >

After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment
Source: Streetwise Reports  (9/6/23)
Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug. More >

FTC Settles Suit, Potentially Averting Further Hurdles
Source: McAlinden Research  (9/6/23)
McAlinden Research shares a deep dive into a market driver with alpha-generating potential. More >

New Vaccine for Chikungunya Shown To Be Safe in Youths
Source: Edward White  (9/1/23)
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report. More >

Approved Drug for Skin Condition Shown Safe at Higher Dose
Source: Dr. Jonathan Aschoff  (9/1/23)
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report. More >

Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023
Source: Streetwise Reports  (8/31/23)
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into. More >

Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.
Source: Scott Henry  (8/29/23)
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report. More >

DNA Tech Co. Launches MRNA Platform and Files Two Patents
Source: Streetwise Reports  (8/29/23)
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock. More >

FDA Approves New Oncology Drug for Clinical Trials
Source: Dr. Robert Driscoll  (8/28/23)
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report. More >

The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside
Source: Ron Struthers  (8/7/23)
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short. More >

Biotech Co. An Attractive Investment
Source: Clive Maund  (8/4/23)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment. More >

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.
Source: Patrick Trucchio  (7/19/23)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. More >

Approval Sought in Japan for New SARS-CoV-2 Vaccine
Source: Ed Arce  (7/7/23)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. More >